Montelukast Medreg (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1 on cells in the respiratory tract. By preventing leukotrienes D4, E4 and F4 from binding, it stops the inflammatory cascade that causes bronchoconstriction, mucus production, and vascular leakage, thereby reducing airway swelling and improving breathing.

The dose of Montelukast Medreg is individualized by the prescribing healthcare professional. Factors such as the patient’s age, weight, severity of the respiratory condition, and response to therapy are considered. The prescriber will select the appropriate strength and dosing schedule based on current clinical guidelines and the patient’s specific needs.

Safety data for Montelukast during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician before starting or continuing therapy.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Montelukast and inhaled corticosteroids (ICS) target different aspects of asthma pathology. Montelukast blocks leukotriene‑mediated inflammation, while ICS reduce overall airway inflammation through glucocorticoid receptors. In many treatment guidelines, Montelukast is used as an add‑on therapy or alternative for patients who cannot tolerate steroids, but it is generally not a substitute for high‑dose ICS in severe cases.

Montelukast Medreg should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in their original blister pack or container, protect them from moisture and direct sunlight, and store them out of reach of children. Do not refrigerate or freeze the product.

Montelukast Medreg is taken orally, usually as a whole tablet with or without food. The exact timing (e.g., morning or evening) and whether it should be taken with a meal are determined by the prescribing clinician based on the individual’s therapeutic plan and convenience.

Serious risks, although rare, include severe allergic reactions such as angioedema, skin disorders like Stevens‑Johnson syndrome, and neuropsychiatric events that may manifest as agitation, depression, or suicidal thoughts. Patients should seek immediate medical attention if they experience any signs of an allergic reaction or significant mood changes.

Montelukast Medreg should be avoided in individuals with a known hypersensitivity to Montelukast or any component of the formulation. Caution is also advised for patients with severe liver impairment, and it should be used only under medical supervision in pregnant or nursing women due to limited safety data.